Original articleLong-term Results of Photodynamic Therapy for Choroidal Neovascularization in Japanese Patients With Pathologic Myopia
Section snippets
Methods
This was a prospective, interventional case series of 60 eyes of 57 consecutive patients with myopic CNV who were treated with PDT between October 2004 and November 2006. Before the approval of the use of an intravitreous injection of bevacizumab (IVB) was obtained from the Ethics Committee of the Tokyo Medical and Dental University, we treated all of the eligible patients with myopic CNV with PDT alone. After December 2006, we switched the treatment for myopic CNV to IVB in all of the eligible
Results
The clinical characteristics of the patients at the initial examination (baseline) are shown in Table 1. Their average age was 53.1 ± 15.9 years, with a range of 19 to 81 years, and the average refractive error (spherical equivalent) of the eyes that were not pseudophakic was −11.6 ± 3.5 D, with a range of −6.5 to −21.0 D. The average axial length was 28.5 ± 1.5 mm, with a range of 26.1 to 32.4 mm. The baseline BCVA was 0.63 ± 0.44 logMAR units, with a range of 0 to 2.0 logMAR units. Thirty-two
Discussion
We studied 48 eyes with myopic CNV: 22 eyes with subfoveal CNV, and 16 eyes with nonsubfoveal CNV. All of the eyes were treated with PDT alone and were followed up for at least 1 year. The mean number of PDT sessions in the 38 eyes was 1.4, with a mean follow-up of 3.2 years. Seventy percent of these eyes obtained angiographic closure by a single PDT. In an earlier study, we reported that patients received an average of 1.4 PDT sessions with a mean follow-up of 15.0 ± 7.0 months.18 These data
Kengo Hayashi, MD, graduated from Okayama University, Japan in 2002, and is now a core member of High Myopia Clinic at Tokyo Medical and Dental University. Dr. Hayashi's interest is on the treatment of myopic choroidal neovascularization.
References (27)
- et al.
Etiology of choroidal neovascularization in young patients
Ophthalmology
(1996) - et al.
Myopic choroidal neovascularization: a 10-year follow-up
Ophthalmology
(2003) - et al.
Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia
Am J Ophthalmol
(2004) - et al.
Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups
Ophthalmology
(2002) - et al.
Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study
Ophthalmology
(2006) - et al.
Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study
Ophthalmology
(2006) - et al.
Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia
Br J Ophthalmol
(2003) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial—VIP report no. 1
Ophthalmology
(2001)- et al.
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—VIP report no. 3
Ophthalmology
(2003) - et al.
Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization
Am J Ophthalmol
(2010)
Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy
Am J Ophthalmol
Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up
Br J Ophthalmol
Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study
Retina
Cited by (40)
Gradual healing of macular retinoschisis after photodynamic therapy for choroidal neovascularization in pathological myopia eyes
2020, Photodiagnosis and Photodynamic TherapyCitation Excerpt :Currently, the management of MRS includes observation and surgical intervention such as pars plana vitrectomy (PPV) and gas tamponade [1,2,4–9]. CNV is a more common cause of visual impairment in both young and elderly patients [5–7]. The treatment of CNV includes photodynamic therapy (PDT) with verteporfin and intravitreal anti-vascular endothelial growth factor (anti-VEGF) such as ranibizumab.
Myopic maculopathy: Current status and proposal for a new classification and grading system (ATN)
2019, Progress in Retinal and Eye ResearchCitation Excerpt :The location of the mCNV has a large influence on final BCVA after PDT. Juxtafoveal lesions have a relatively smaller chorioretinal atrophy area and better BCVA compared to subfoveal lesions (Hayashi et al., 2011). Several authors support the use of PDT to treat juxtafoveal lesions, but PDT carries a substantial risk of increasing the size of the CNV, as studies have shown that a juxtafoveal CNV can become a subfoveal CNV after PDT (Bandello et al., 2003).
Choroidal Neovascularization Secondary to Diseases Other than Age-Related Macular Degeneration
2017, Choroidal Disorders
Kengo Hayashi, MD, graduated from Okayama University, Japan in 2002, and is now a core member of High Myopia Clinic at Tokyo Medical and Dental University. Dr. Hayashi's interest is on the treatment of myopic choroidal neovascularization.